Trimeprazine Tartrate;Prednisolone

Verify with FDA CVM →

315 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
315
Total Reports
37
Deaths Reported
1170.0%
Death Rate

Active Ingredients

Trimeprazine Tartrate;Prednisolone

Administration Routes

OralUnknown

Species Affected

Dog 294
Unknown 19
Other 1
Cat 1

Most Affected Breeds

Chihuahua 24
Retriever - Labrador 22
Unknown 20
Shih Tzu 18
Maltese 13
Dog (unknown) 13
Terrier - Yorkshire 12
Retriever - Golden 10
Bulldog - French 10
Shepherd Dog - German 9

Most Reported Reactions

Lack of efficacy - NOS 64
Vomiting 41
Lethargy (see also Central nervous system depression in 'Neurological') 36
Diarrhoea 26
Panting 22
Cough 22
Seizure NOS 20
Death 19
Polydipsia 19
Anorexia 17
Elevated serum alkaline phosphatase (SAP) 17
Polyuria 17

Outcome Breakdown

Ongoing
185 (62.5%)
Outcome Unknown
45 (15.2%)
Recovered/Normal
28 (9.5%)
Died
22 (7.4%)
Euthanized
15 (5.1%)
Recovered with Sequela
1 (0.3%)

Data Summary

Metric Value
Total adverse event reports 315
Reports involving death 37
Case-fatality rate (reported events) 1170.0%
Distinct species in reports 4
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Trimeprazine Tartrate;Prednisolone Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 315 adverse event reports referencing Trimeprazine Tartrate;Prednisolone, including 37 reports in which the animal died — a 1170.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Trimeprazine Tartrate;Prednisolone. Reported administration routes include Oral, Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Trimeprazine Tartrate;Prednisolone reports are Dog (294 reports), Unknown (19 reports), Other (1 reports), with Dog accounting for the largest share. Within those species, Chihuahua (24), Retriever - Labrador (22), Unknown (20) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Trimeprazine Tartrate;Prednisolone are Lack of efficacy - NOS (64), Vomiting (41), Lethargy (see also Central nervous system depression in 'Neurological') (36), Diarrhoea (26). Of the 296 reports with a coded outcome, Ongoing is the leading category at 62.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Trimeprazine Tartrate;Prednisolone.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial